Lindtner, R A <br/><br/>
Osteoanabolic effect of alendronate and zoledronate on bone marrow stromal cells (BMSCs) isolated from aged female osteoporotic patients and its implications for their mode of action in the treatment of age-related bone loss.  [electronic resource] 

 -  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA  Mar 2014 
 - 1151-61 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1433-2965 
<br/><br/><label>Standard No.: </label>10.1007/s00198-013-2494-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Alendronate--pharmacology<br/>Alkaline Phosphatase--metabolism<br/>Bone Density--drug effects<br/>Bone Density Conservation Agents--pharmacology<br/>Cell Differentiation--drug effects<br/>Cells, Cultured<br/>Diphosphonates--pharmacology<br/>Female<br/>Humans<br/>Imidazoles--pharmacology<br/>Mesenchymal Stem Cells--drug effects<br/>Osteogenesis--drug effects<br/>Osteopontin--physiology<br/>Osteoporosis, Postmenopausal--drug therapy<br/>Zoledronic Acid